This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. KLRS, DTIL, ELYM, INKT, ANVS, ALGS, TELO, OSTX, ATNM, and PRLDShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Kalaris Therapeutics (KLRS), Precision BioSciences (DTIL), Eliem Therapeutics (ELYM), MiNK Therapeutics (INKT), Annovis Bio (ANVS), Aligos Therapeutics (ALGS), Telomir Pharmaceuticals (TELO), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors Kalaris Therapeutics Precision BioSciences Eliem Therapeutics MiNK Therapeutics Annovis Bio Aligos Therapeutics Telomir Pharmaceuticals OS Therapies Actinium Pharmaceuticals Prelude Therapeutics TenX Keane Acquisition (NASDAQ:TENK) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Which has stronger valuation and earnings, TENK or KLRS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenX Keane AcquisitionN/AN/AN/AN/AN/AKalaris TherapeuticsN/AN/A-$58.77MN/AN/A Is TENK or KLRS more profitable? TenX Keane Acquisition's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TenX Keane AcquisitionN/A N/A N/A Kalaris Therapeutics N/A -81.02%-65.15% Does the media refer more to TENK or KLRS? In the previous week, Kalaris Therapeutics had 3 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 0 mentions for TenX Keane Acquisition. TenX Keane Acquisition's average media sentiment score of 0.00 beat Kalaris Therapeutics' score of -0.38 indicating that TenX Keane Acquisition is being referred to more favorably in the media. Company Overall Sentiment TenX Keane Acquisition Neutral Kalaris Therapeutics Neutral Do insiders and institutionals hold more shares of TENK or KLRS? 70.5% of TenX Keane Acquisition shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 22.9% of TenX Keane Acquisition shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend TENK or KLRS? Kalaris Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 21.95%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryTenX Keane Acquisition and Kalaris Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$11.44M$224.26M$2.07B$9.83BDividend YieldN/A3.23%13.66%4.08%P/E RatioN/A1.9712.2825.12Price / SalesN/A522.372,997,338.20116.12Price / CashN/A115.7757.5359.05Price / BookN/A8.383.096.18Net IncomeN/A-$10.81M-$456.46M$264.89M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$1.72-3.9%N/A-27.5%$11.44MN/A0.00N/AHigh Trading VolumeKLRSKalaris Therapeutics1.2669 of 5 stars$2.71+2.7%$3.00+10.7%N/A$50.68MN/A0.00110Earnings ReportGap DownDTILPrecision BioSciences4.1957 of 5 stars$4.57-5.0%$47.00+928.4%-46.8%$50.67M$51.14M-2.27200Analyst RevisionGap DownELYMEliem TherapeuticsN/A$1.70+17.2%N/A-72.9%$50.58MN/A-3.219High Trading VolumeINKTMiNK Therapeutics3.1199 of 5 stars$12.66-3.1%$37.50+196.2%+82.4%$50.51MN/A-5.0230News CoverageEarnings ReportAnalyst UpgradeShort Interest ↓Gap UpANVSAnnovis Bio2.6517 of 5 stars$2.59-3.0%$18.00+595.0%-64.6%$50.47MN/A-1.203News CoverageEarnings ReportGap UpALGSAligos Therapeutics4.435 of 5 stars$8.13+1.1%$70.00+761.0%-38.4%$49.71M$3.27M-0.4690News CoverageTELOTelomir Pharmaceuticals2.5978 of 5 stars$1.67-9.2%$15.00+798.2%-58.8%$49.70MN/A-3.981Earnings ReportOSTXOS Therapies2.4444 of 5 stars$1.75flat$18.00+928.6%-33.0%$49.17MN/A-2.03N/ANews CoverageHigh Trading VolumeATNMActinium Pharmaceuticals2.937 of 5 stars$1.56-2.5%$4.50+188.5%-15.6%$48.67MN/A-1.1230News CoveragePositive NewsShort Interest ↓Analyst RevisionPRLDPrelude Therapeutics3.0543 of 5 stars$0.86+0.8%$4.50+425.1%-81.7%$48.39M$7M-0.51120News CoverageEarnings Report Related Companies and Tools Related Companies KLRS Alternatives DTIL Alternatives ELYM Alternatives INKT Alternatives ANVS Alternatives ALGS Alternatives TELO Alternatives OSTX Alternatives ATNM Alternatives PRLD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access